EGFR OverexpressionPhase 1/2NCT06975410
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
A Phase 1/2 study testing YH32364 in people with EGFR Overexpression and Locally Advanced Solid Tumor, run by Yuhan Corporation at 4 sites in South Korea.
Trial summary
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- What is being tested?
- YH32364
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 4 sitesSouth Korea
- Study dates
- 12 Jun 2025to Dec 2029
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must sign an informed consent form (ICF) prior to any study specific procedures
- ECOG performance status 0 or 1
- Estimated life expectancy of at least 3 months
- A woman must not be breastfeeding
- Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements.
- [Dose Escalation Only] Locally advanced or metastatic EGFR overexpressing solid tumor that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy
Show all 16Show fewer
- One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors.
- Head and neck squamous cell carcinoma (HNSCC)
- Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC)
- Esophageal squamous cell carcinoma (ESCC)
- Biliary tract cancer (BTC)
- Uterine cervical cancer
- Vulvar cancer
- Urothelial cancer
- Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor)
- [Dose Expansion Only] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC) that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy.
Who cannot join
- Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis
- Have history of a second primary cancer with the exception of
- curatively treated non-melanomatous skin cancer
- curatively treated cervical or breast carcinoma in situ, or
- other malignancy with no known active disease present and no treatment administered during the last 2 years
- Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)
Show all 18Show fewer
- Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks
- Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis
- Have autoimmune disease that has required systemic treatment
- Infection with human immunodeficiency virus (HIV)
- Active chronic hepatitis B or chronic hepatitis C
- [Prior/Concomitant Therapy]
- Have received systemic steroid therapy
- Previous treatment with a 4-1BB/CD137-modulating agent
- Have used a live vaccine within 4 weeks
- Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies
- Have received radiation therapy
- Have received cytotoxic chemotherapy
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea4 sites, 4 recruiting
- Recruiting
Korea University Anam Hospital
Seoul, 02841
- Recruiting
Seoul National University Hospital
Seoul, 03080
- Recruiting
Severance Hospital
Seoul, 03722
- Recruiting
Samsung Medical Center
Seoul, 06351
About this study
Official title: A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
Read the detailed description
YH32364 is a new type of immunotherapy called a bispecific antibody that targets both Epidermal Growth Factor Receptor (EGFR) and 4-1BB. EGFR is a gene involved in cancer growth, and many cancer treatments aim to target it. 4-1BB, an immune-modulating protein, plays an important role in boosting T cell activity to combat cancer.
YH32364 is a treatment designed to activate 4-1BB specifically in tumors, aiming to avoid the liver-related side effects seen with previous 4-1BB treatments. It also helps block EGFR signals, assumed to make EGFR-targeted therapies more effective by overcoming resistance.
This study is consists of two parts. In Part 1, participants will be assigned sequentially to one of six dose levels, ranging from the lowest to the highest dose as determined by the sponsor, in order to identify an appropriate dosage.
In Part 2, participants will be randomly assigned to one of the two optimal dose levels identified in Part 1 to confirm the recommended dose.
The YH32364 will be administered via intravenous (IV) infusion once every two weeks. Participants will be required to visit the study site regularly for treatment and assessments. During all the visits, the doctors check participants' health and take note of any unwanted effects.
- Being tested
- YH32364
- Keywords
- YH32364, EGFR/4-1BB bispecific antibody, Solid tumor, Head and neck squamous cell carcinoma (HNSCC), Non-small cell lung cancer (NSCLC), Esophageal squamous cell carcinoma (ESCC), Biliary tract cancer (BTC), Uterine cervical cancer, Vulvar cancer, Urothelial cancer
- Medical subject headings
- Neoplasm Metastasis, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
YH32364Drug
Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose.
Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be randomized 1:1 ratio to each dose. (Cohort 1: Participants with locally advanced or metastatic EGFR overexpressing HNSCC other than NPC, whose disease progressed after or who are intolerable to all the available standard treatment)
| Study group | Role | What they receive |
|---|---|---|
| YH32364 | Experimental | Dose Escalation Part: Dose Escalation part is designed to assess the safety and tolerability of YH32364 and to identify the Maximum Tolerated dose (MTD) and/or two dose levels for recommended dose (RD) selection.
Dose Expansion Part: Dose Expansion part will consist of multiple cohorts by cancer types. Cohort 1 will be initiated to determine the RD after completion of Part 1. The RD will be determined among two dose levels investigated in Cohort 1 based on the totality of available data including PK, biomarkers, dose-response, safety, and efficacy. Receives: Drug: YH32364 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs)
To assess the safety and tolerability of YH32364 in order to determine maximum tolerated dose (MTD) and select doses for dose optimization
Measured: Study Day 1 to Study Day 28 (during the DLTs evaluation period)
Objective Response Rate (ORR)
To assess the ORR of YH32364 at the recommended dose (RD) according to RECIST v1.1 by Investigator assessment
Measured: through dose expansion part completion, approximately 1.5 year
Secondary outcomes (23)
Area under the serum concentration-time curve from time 0 to the last quantifiable concentration (AUClast)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
AUC from time 0 to infinity (AUCinf)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Maximum observed serum concentration (Cmax)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Time to reach Cmax (Tmax)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Apparent terminal elimination half-life (t1/2)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Total clearance (CL)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Volume of distribution (Vd)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Volume of distribution at steady state (Vss)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
AUC during dosing interval at steady state (AUCtau)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Cmax at steady state (Cmax,ss)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Time to reach Cmax,ss (Tmax,ss)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Accumulation ratio (Rac)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Trough (predose) serum concentration on Cycle 4 (Ctrough)
To characterize the pharmacokinetics (PK) of YH32364
Measured: through study completion, approximately 2.5 year
Presence and characterization of YH32364 ADA including neutralizing antibodies
To explore the immunogenicity of YH32364
Measured: through study completion, approximately 2.5 year
Titer of YH32364 ADA
To explore the immunogenicity of YH32364
Measured: through study completion, approximately 2.5 year
Objective Response Rate (ORR)
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
Measured: through dose escalation part completion, approximately 1 year
Duration of Response (DoR)
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
Measured: through study completion, approximately 2.5 year
Disease Control Rate (DCR)
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
Measured: through study completion, approximately 2.5 year
Depth of Response
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
Measured: through study completion, approximately 2.5 year
Time to Response
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
Measured: through study completion, approximately 2.5 year
Progression-free survival (PFS)
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
Measured: through study completion, approximately 2.5 year
TEAEs
To assess the safety and tolerability of YH32364
Measured: through dose expansion part completion, approximately 1.5 year
Overall Survival (OS)
To assess the overall survival of YH32364 at the RD
Measured: through dose expansion part completion, approximately 1.5 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2025
- Study start12 Jun 2025
- Primary completionJun 2027 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EGFR OverexpressionStudies of the same condition, open and under way.
- More trials run by Yuhan CorporationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yuhan Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Yuhan Clinical Research Physician, Study director, Yuhan Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06975410
- Sponsor's protocol ID
- YH32364-101
- Status last verified
- Jun 2026
- First submitted
- 28 Apr 2025
- Last updated
- 10 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to clinicaltrials@yuhan.co.kr A summary of the study results will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors
- ClinicalTrials.gov ID
- NCT06975410
- Acronym / sponsor ID
- YH32364-101
- Keywords
- YH32364, EGFR/4-1BB bispecific antibody, Solid tumor, Head and neck squamous cell carcinoma (HNSCC), Non-small cell lung cancer (NSCLC), Esophageal squamous cell carcinoma (ESCC), Biliary tract cancer (BTC), Uterine cervical cancer
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Yuhan CorporationIndustry (pharma, biotech, devices)
- Study start
- 12 Jun 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 16 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
Detailed description
YH32364 is a new type of immunotherapy called a bispecific antibody that targets both Epidermal Growth Factor Receptor (EGFR) and 4-1BB. EGFR is a gene involved in cancer growth, and many cancer treatments aim to target it. 4-1BB, an immune-modulating protein, plays an important role in boosting T cell activity to combat cancer.
YH32364 is a treatment designed to activate 4-1BB specifically in tumors, aiming to avoid the liver-related side effects seen with previous 4-1BB treatments. It also helps block EGFR signals, assumed to make EGFR-targeted therapies more effective by overcoming resistance.
This study is consists of two parts. In Part 1, participants will be assigned sequentially to one of six dose levels, ranging from the lowest to the highest dose as determined by the sponsor, in order to identify an appropriate dosage.
In Part 2, participants will be randomly assigned to one of the two optimal dose levels identified in Part 1 to confirm the recommended dose.
The YH32364 will be administered via intravenous (IV) infusion once every two weeks. Participants will be required to visit the study site regularly for treatment and assessments. During all the visits, the doctors check participants' health and take note of any unwanted effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| YH32364 | Experimental | Drug: YH32364Dose Escalation Part: Dose Escalation part is designed to assess the safety and tolerability of YH32364 and to identify the Maximum Tolerated dose (MTD) and/or two dose levels for recommended dose (RD) selection. Dose Expansion Part: Dose Expansion part will consist of multiple cohorts by cancer types. Cohort 1 will be initiated to determine the RD after completion of Part 1. The RD will be determined among two dose levels investigated in Cohort 1 based on the totality of available data including PK, biomarkers, dose-response, safety, and efficacy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Must sign an informed consent form (ICF) prior to any study specific procedures
- ECOG performance status 0 or 1
- Estimated life expectancy of at least 3 months
- A woman must not be breastfeeding
- Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements.
Key exclusion criteria (18 listed)
- Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis
- Have history of a second primary cancer with the exception of
- Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)
- Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks
- Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| YH32364Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose. Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be randomized 1:1 ratio to each dose. (Cohort 1: Participants with locally advanced or metastatic EGFR overexpressing HNSCC other than NPC, whose disease progressed after or who are intolerable to all the available standard treatment) | Drug | YH32364 |
Primary outcome
Treatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs)
Time frame: Study Day 1 to Study Day 28 (during the DLTs evaluation period)
To assess the safety and tolerability of YH32364 in order to determine maximum tolerated dose (MTD) and select doses for dose optimization
Objective Response Rate (ORR)
Time frame: through dose expansion part completion, approximately 1.5 year
To assess the ORR of YH32364 at the recommended dose (RD) according to RECIST v1.1 by Investigator assessment
23 secondary outcomes
Area under the serum concentration-time curve from time 0 to the last quantifiable concentration (AUClast)
Time frame: through study completion, approximately 2.5 year
AUC from time 0 to infinity (AUCinf)
Time frame: through study completion, approximately 2.5 year
Maximum observed serum concentration (Cmax)
Time frame: through study completion, approximately 2.5 year
Time to reach Cmax (Tmax)
Time frame: through study completion, approximately 2.5 year
Apparent terminal elimination half-life (t1/2)
Time frame: through study completion, approximately 2.5 year
Total clearance (CL)
Time frame: through study completion, approximately 2.5 year
Volume of distribution (Vd)
Time frame: through study completion, approximately 2.5 year
Volume of distribution at steady state (Vss)
Time frame: through study completion, approximately 2.5 year
AUC during dosing interval at steady state (AUCtau)
Time frame: through study completion, approximately 2.5 year
Cmax at steady state (Cmax,ss)
Time frame: through study completion, approximately 2.5 year
Time to reach Cmax,ss (Tmax,ss)
Time frame: through study completion, approximately 2.5 year
Accumulation ratio (Rac)
Time frame: through study completion, approximately 2.5 year
Trough (predose) serum concentration on Cycle 4 (Ctrough)
Time frame: through study completion, approximately 2.5 year
Presence and characterization of YH32364 ADA including neutralizing antibodies
Time frame: through study completion, approximately 2.5 year
Titer of YH32364 ADA
Time frame: through study completion, approximately 2.5 year
Objective Response Rate (ORR)
Time frame: through dose escalation part completion, approximately 1 year
Duration of Response (DoR)
Time frame: through study completion, approximately 2.5 year
Disease Control Rate (DCR)
Time frame: through study completion, approximately 2.5 year
Depth of Response
Time frame: through study completion, approximately 2.5 year
Time to Response
Time frame: through study completion, approximately 2.5 year
Progression-free survival (PFS)
Time frame: through study completion, approximately 2.5 year
TEAEs
Time frame: through dose expansion part completion, approximately 1.5 year
Overall Survival (OS)
Time frame: through dose expansion part completion, approximately 1.5 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to clinicaltrials@yuhan.co.kr A summary of the study results will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.
Related trials for EGFR Overexpression
RecruitingPhase 1/2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Solid Tumors
RecruitingPhase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer, c-MET
RecruitingPhase 3
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Esophageal Cancer
RecruitingPhase 1
HER-2 B Cell Peptide Vaccine
Metastatic Breast Cancer, HER2-positive Breast Cancer
RecruitingPhase 3
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Locally Advanced or Metastatic NSCLC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yuhan Clinical Research Physician study director
Yuhan Corporation
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing YH32364 in people with EGFR Overexpression and Locally Advanced Solid Tumor, run by Yuhan Corporation at 4 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Operation Team 1 (+82-2-828-0150, clinicaltrials@yuhan.co.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs) (time frame: Study Day 1 to Study Day 28 (during the DLTs evaluation period)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.